OTC nicotine patches
This article was originally published in The Tan Sheet
Executive Summary
Use of SmithKline Beecham's NicoDerm CQ smoking cessation patch (21 mg) results in better heart rate variability (HRV) among post-MI patients than individuals randomized to a placebo patch, Phyllis Stein, Washington University School of Medicine, et al., report in a poster presented at the ACC meeting in Anaheim March 12-15. The study compared the HRV effect of smoking cessation among 18 people - nine wearing the NicoDerm patch and nine the placebo - for a four-week period. Holter recordings were taken at baseline and at the end of the month. "Smoking cessation using transdermal nicotine patches compared with quitting cold turkey resulted in more 'favorable' changes in HRV," the researchers state. The findings suggest the need for further study in a larger population, Stein et al. conclude
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning